Loading quotes...

Forecast

The analysts' average price target is €54.73 (+164.40%). The median is €58.32 (+181.74%).

Buy	14
Hold	6
Sell	0

News Go to news feed

Legend Biotech plunges despite record quarter and first profitable quarter

Legend Biotech's stock fell about 2.4% in pre-market trading despite a surprisingly strong second quarter with adjusted EPS of $0.16 (consensus $0.07) and revenue of $387.5 million. The company thus reported its first profitable quarter, but a "sell-the-news" reaction was amplified by Oppenheimer's downgrade (Outperform → Perform, price target $75 → $40), earlier analyst cuts, and the CEO's resignation. Analysts also warn of growing competition for CARVYKTI and a lack of near-term catalysts. The decline is reported to be company-specific, while US indexes rose slightly. » More on de.investing.com
Legend Biotech beats Q2 expectations and achieves company-wide profitability

Legend Biotech reported adjusted EPS of $0.16 and revenue of $387.5 million for Q2, both above consensus estimates. The company recorded its first profitable quarter on both an IFRS and adjusted basis, driven by global CARVYKTI revenue of about $657 million (+50% year/year). Management expects continued adjusted profitability in H2 2026, plans an IND filing for LB2501 in 2026, and targets long-term gross margins of around 75%, but warns of margin volatility and leadership uncertainty. The stock rose about 5% in premarket trading. » More on de.investing.com
Legend Biotech CEO Ying Huang resigns, Alan Bash named interim CEO

Legend Biotech announced the abrupt resignation of CEO Ying Huang on July 24, saying the departure was not due to any disagreement with the company. President of the Carvykti business unit Alan Bash will serve as interim CEO while the company searches for a permanent replacement. Legend highlighted Carvykti's strong commercial performance and said it remains focused on execution amid growing competitive and regulatory scrutiny. » More on finance.yahoo.com

Financials

In the last quarter, Legend Biotech ADR had revenue of €339.53m and net profit of €29.09m

(EUR)	June 2026	YoY
Revenue	339.53m	56.90%
Gross profit	219.14m	64.45%
Net profit	29.09m	127.35%
EBITDA	60.81m	163.02%

Fundamentals

Metric	Value
Market capitalization	€3.74bn
Number of shares	184.94m
52-week high/low	€33.64 - €14.57
Dividends	No
Beta	0.40
P/E ratio	-45.08
PEG ratio	-0.55
P/B ratio	3.43
P/S ratio	3.28

Company profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.